

Table of contents

Preface	347
M. S. TALLMAN	
1 Morphological and cytochemical characteristics of leukaemic promyelocytes	349
V. LISO & J. BENNETT	
2 The epidemiology of acute promyelocytic leukaemia	357
D. DOUER	
3 Expression of cell-surface antigens in acute promyelocytic leukaemia	369
E. PAIETTA	
4 Molecular pathogenesis of acute promyelocytic leukaemia and APL variants	387
A. SIRULNIK, A. MELNICK, A. ZELENT & J. D. LICHT	
5 FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors	409
D. G. GILLILAND	
6 All- <i>trans</i> retinoic acid in acute promyelocytic leukaemia	419
G. AVVISATI & M. S. TALLMAN	
7 Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia	433
M. A. SANZ, G. MARTÍN & F. LO COCO	
8 Retinoic acid syndrome: manifestations, pathogenesis, and treatment	453
R. S. LARSON & M. S. TALLMAN	
9 Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia	463
A. FALANGA & F. R. RICKLES	
10 Acute promyelocytic leukaemia in children	483
J. GREGORY JR. & J. FEUSNER	
11 Treatment of older adults with acute promyelocytic leukaemia	495
P. FENAUX, S. CHEVRET & S. DE BOTTON	
12 The importance of molecular monitoring in acute promyelocytic leukaemia	503
F. LO-COCO, M. BRECCIA & D. DIVERIO	
13 Treatment options for relapsed acute promyelocytic leukaemia	521
E. H. ESTEY	
14 Long-term follow-up and potential for cure in acute promyelocytic leukaemia	535
M. S. TALLMAN & J. M. ROWE	
Index	I